TLDR
- Iovance Biotherapeutics (IOVA) raised its full-year 2026 revenue guidance to $410 million-$420 million, up from $350 million-$370 million.
- The new midpoint of $415 million clears the analyst consensus estimate of $402.8 million.
- The stock climbed more than 14% in premarket trading Tuesday on the news.
- Demand for cell therapy Amtagvi and continued Proleukin sales are driving the higher outlook.
- Iovance plans to grow its authorized treatment center network to at least 110 locations by the end of 2026.
Iovance Biotherapeutics (IOVA) stock climbed more than 14% in premarket trading Tuesday. The move came after the company raised its full-year 2026 revenue guidance well above what analysts had penciled in.
Iovance Biotherapeutics, Inc., IOVA
The commercial-stage biotech now expects total revenue of $410 million to $420 million for 2026. That’s up from its prior range of $350 million to $370 million.
At the midpoint, that’s a $55 million increase and represents close to 60% annual revenue growth. It also clears the Street’s consensus estimate of $402.8 million.
Iovance credited strong U.S. demand for its flagship therapy Amtagvi, along with steady sales of Proleukin, for the upgraded forecast. Interim president and CEO Frederick Vogt called it a record second quarter for the company.
“Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint,” Vogt said.
What’s Behind the Raise
The updated forecast follows a broader financial review that started alongside second-quarter results. Those results included record product revenue of $99.3 million.
Management pointed to solid patient demand and a well-timed manufacturing schedule as reasons for the improved visibility heading into the back half of the year. That combination gave leadership enough confidence to bump up the full-year number.
Amtagvi is a one-time cell therapy used to treat advanced melanoma. It’s built on tumor-infiltrating lymphocyte technology, a treatment approach still fairly new to the oncology market.
Expanding Patient Access
Iovance has been growing its commercial footprint alongside the guidance increase. The company’s authorized treatment center network now sits at around 100 locations.
That number is expected to keep climbing. Iovance says it remains on pace to reach at least 110 authorized centers by the end of 2026.
More treatment centers means wider access to Amtagvi for patients with advanced melanoma. It’s a key piece of the company’s growth story beyond just the sales numbers.
Beyond commercial execution, Iovance also pointed to operational efficiencies and manufacturing refinements. Those improvements are said to be speeding up the company’s path toward profitability.
On the clinical side, lifileucel, the active ingredient behind Amtagvi, continues moving through trials. The company is working to secure approvals in additional solid tumor indications beyond melanoma.
Investors will get another look at the numbers soon. Iovance is set to report full third-quarter financial results in early November.
The premarket pop Tuesday reflected the market’s reaction to the higher guidance range. IOVA stock traded up double digits as the session got underway.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment